Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA approves Novartis’ oral multiple sclerosis drug Mayzent

pharmaceutical-technologyApril 11, 2019

Tag: FDA , Novartis , Mayzent , SPMS , RRMS

PharmaSources Customer Service